You are here

  • Home
  • Archive
  • Volume 12, Issue 7
  • Supervised injectable opioid agonist therapy in a supported housing setting for the treatment of severe opioid use disorder

Article Text

Article menu
Download PDFPDF
Novel treatment (new drug/intervention; established drug/procedure in new situation)
CASE REPORT
Supervised injectable opioid agonist therapy in a supported housing setting for the treatment of severe opioid use disorder
  1. Rupinder Brar1,
  2. Christy Sutherland1 and
  3. Seonaid Nolan2
  1. 1 Family Practice, University of British Columbia, Vancouver, British Columbia, Canada
  2. 2 Medicine, University of British Columbia, Vancouver, British Columbia, Canada
  1. Correspondence to Dr Seonaid Nolan, seonaid.nolan{at}bccsu.ubc.ca

Abstract

Currently, North America is facing a national opioid overdose crisis. Opioid use disorder (OUD) is a chronic, relapsing condition requiring varying intensities of treatment. Injectable opioid agonist therapy (iOAT) is an effective, high-intensity treatment option for people who are unsuccessful on conventional oral opioid agonist treatments (eg, methadone, buprenorphine). This case highlights the effectiveness of the provision of iOAT in a low-barrier setting. More specifically, we discuss a patient with severe OUD and untreated HIV infection, who was disengaged from medical care and, consequently, was prescribed iOAT in a supportive housing setting.

  • general practice / family medicine
  • HIV/AIDS
  • drug misuse (including addiction)

https://doi.org/10.1136/bcr-2019-229456

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Contributors RB is the primary author as she drafted this case report. She worked closely with CS who is the treating physician, and CS provided detailed guidance. SN is RB’s supervisor and guided her along the way and edited all drafts of this manuscript.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; externally peer reviewed.

    • Patient consent for publication Obtained.